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Introduction {#sec1}
============

Primary and secondary prevention strategies that reduce sun exposure and encourage increased sun protection and skin examination behaviors are important for reducing melanoma incidence and mortality, particularly for those identified as being at high risk ([@bib1], [@bib2], [@bib5], [@bib21]). To date, identifying people at high risk for melanoma has focused on factors such as family history ([@bib35]), phenotypic characteristics (fair skin, skin that burns easily, red hair, moles and freckling ([@bib18]), solar and artificial UV radiation exposure ([@bib10], [@bib19]), and previous keratinocyte skin cancers ([@bib19]).

Common genomic variants may help identify people at high risk for melanoma, particularly those who lack these traditional risk factors ([@bib4], [@bib11], [@bib26]). It is becoming more feasible to incorporate genomic profiles into risk prediction tools, given increased understanding of genomic risk factors and increased genomic testing in clinical practice. Development and assessment of melanoma risk prediction models that combine traditional and genomic risk factors is warranted to help improve melanoma prevention and population screening. For example, Australian general practice guidelines state that clinical assessment of melanoma risk should take into account multiple risk factors yet highlight the fact that there are no sufficiently well-validated risk models to assess the combined effects of all risk factors ([@bib40]). Accurate identification of people at high risk for melanoma will also facilitate research on targeted screening strategies for those at higher risk ([@bib45]).

Few studies have examined the contribution of multiple genomic risk factors to risk prediction over and above that of traditional risk factors ([@bib17], [@bib27], [@bib42]). Limitations of previous studies have included lack of external validation, small sample size ([@bib42]), lack of data on nevus phenotype or family history ([@bib17], [@bib27], [@bib42]), and possible confounding by ethnicity ([@bib17]).

We aimed to evaluate the incremental contribution of common genomic variants to melanoma risk prediction, including the contribution of variants associated with identified biological pathways, using data from two population-based studies in geographically disparate but genetically similar populations (Australia and the UK). Both studies were developed by the GenoMEL ([www.genomel.org](http://www.genomel.org){#intref0010}) melanoma genetics consortium and used the same measurement protocols, facilitating external validation.

Results {#sec2}
=======

Participant characteristics {#sec2.1}
---------------------------

Demographic characteristics of participants in the Australian and Leeds, UK, case-control studies in this analysis are shown in [Table 1](#tbl1){ref-type="table"}. The studies had a similar proportion (60%) of female participants but a slightly different mix of European ethnicities; results were similar if restricted to English ethnic background. Participants were younger in the Australian study because it restricted recruitment to onset before age 40 years.Table 1Characteristics of case and control individuals in the Australian Melanoma Family Study and Leeds case-control studyCharacteristicAustralia, n (%)Leeds, n (%)Total, case and control individuals1,0351,460 Case individuals578 (56)964 (66) Control individuals457 (44)496 (34)Sex Female623 (60)874 (60) Male412 (40)586 (40)Age at diagnosis/interview, years[1](#tbl1fn1){ref-type="table-fn"} 18--29268 (26)61 (4) 30--39682 (66)198 (14) 40--4985 (8)264 (18) ≥50--690 (0)937 (64)Ethnic background[2](#tbl1fn2){ref-type="table-fn"} English649 (63)1,358 (93) Scottish, Irish, Welsh52 (5)67 (5) Other Northern European46 (4)6 (0) Southern European11 (1)6 (0) Eastern European238 (23)3 (0) Mixed/other European39 (4)20 (1)[^3][^4]

Association of polygenic risk score with melanoma risk {#sec2.2}
------------------------------------------------------

For each country, there was a 3-fold higher risk of melanoma for participants in the highest versus lowest tertile of polygenic risk score and a 6-fold higher risk in the highest versus lowest decile; the odds ratio (OR) per adjusted standard deviation increase in polygenic score (i.e., OPERA) was 1.75 for Australia and 1.63 for Leeds ([Table 2](#tbl2){ref-type="table"}). When evaluated by biological pathway (see [Supplementary Table S1](#appsec1){ref-type="sec"} online) the ORs for the pigmentation pathway were similar to the overall polygenic risk score, but the ORs were lower for the telomere/senescence/other pathway (about 50% increased risk for the highest vs. lowest tertile) and the nevus pathway (about 25% nonsignificantly increased risk for the highest vs. lowest tertile).Table 2Association of an overall polygenic risk score with melanoma risk in the Australia and Leeds studiesOverall Polygenic\
Risk ScoreAustraliaLeedsRangeCase Individuals,\
n (%)Control Individuals,\
n (%)Odds Ratio[1](#tbl2fn1){ref-type="table-fn"}\
(95% CI)RangeCase Individuals,\
n (%)Control Individuals,\
n (%)Odds Ratio[1](#tbl2fn1){ref-type="table-fn"}\
(95% CI)Tertiles 1--2.11 to 0.16103 (18)152 (33)1.00--1.46 to 0.16160 (17)163 (33)1.00 20.16 to 0.60158 (27)170 (37)1.38 (0.97--1.94)0.16 to 0.60312 (32)154 (31)2.09 (1.56--2.82) 30.60 to 2.52317 (55)135 (30)3.22 (2.30--4.51)0.60 to 2.69492 (51)179 (36)2.84 (2.14--3.77) *P* trend\<0.0001\<0.0001 *P* int[2](#tbl2fn2){ref-type="table-fn"}0.29Deciles 1--2.11 to --0.2624 (4)43 (9)1.00--1.46 to --0.2748 (5)53 (11)1.00 2--0.26 to --0.0523 (4)45 (10)0.93 (0.45--1.94)--0.26 to --0.0538 (4)50 (10)0.88 (0.49--1.58) 3--0.05 to 0.1337 (6)43 (9)1.47 (0.73--2.94)--0.05 to 0.1364 (7)52 (10)1.45 (0.84--2.50) 40.13 to 0.2751 (9)54 (12)1.83 (0.95--3.54)0.13 to 0.2783 (9)42 (8)2.36 (1.36--4.10) 50.28 to 0.3754 (9)76 (17)1.23 (0.65--2.32)0.27 to 0.3757 (6)41 (8)1.61 (0.91--2.84) 60.37 to 0.4941 (7)30 (7)2.51 (1.23--5.13)0.37 to 0.49109 (11)43 (9)2.99 (1.75--5.10) 70.49 to 0.6349 (8)41 (9)2.13 (1.08--4.18)0.49 to 0.6391 (9)55 (11)1.94 (1.14--3.27) 80.64 to 0.8277 (13)44 (10)3.06 (1.60--5.83)0.64 to 0.83106 (11)51 (10)2.44 (1.45--4.12) 90.83 to 1.0673 (13)38 (8)3.03 (1.56--5.88)0.83 to 1.06118 (12)57 (11)2.44 (1.46--4.08) 101.06 to 2.52149 (26)43 (9)5.88 (3.14--11.03)1.06 to 2.69250 (26)52 (10)5.62 (3.41--9.29) *P* trend\<0.0001\<0.0001 *P* int[2](#tbl2fn2){ref-type="table-fn"}0.28OPERA[3](#tbl2fn3){ref-type="table-fn"}1.75 (1.53--2.01)1.63 (1.46--1.83) *P* int[2](#tbl2fn2){ref-type="table-fn"}0.40[^5][^6][^7]

Incremental contribution of polygenic risk score based on published risk estimates {#sec2.3}
----------------------------------------------------------------------------------

Adding the polygenic risk score based on published ORs to a model with traditional risk factors increased the AUC by 2.3% (*P* = 0.003) for Australia and by 2.8% (*P* = 0.002) for Leeds ([Table 3](#tbl3){ref-type="table"}). The net reclassification improvement (NRI) was 0.42 (95% confidence interval \[CI\] = 0.30--0.54) for Australia and 0.29 (95% CI = 0.18--0.39) for Leeds; this was driven more by improvements in specificity (i.e., net movement of control individuals to a lower risk: 29% in Australia and 19% in Leeds) than in sensitivity (net movement of case individuals to a higher risk: 13% in Australia, 9% in Leeds). Single nucleotide polymorphisms (SNPs) in the pigmentation pathway, particularly *MC1R*, were responsible for most of the incremental improvement. Conversely, SNPs in the nevus and other pathways did not significantly improve risk prediction. Most models were well calibrated except for the addition of the nevus pathway SNPs in Australia.Table 3Incremental contribution of genetic risk factors to risk prediction of melanoma when added to a traditional risk factor model, based on published risk estimatesRisk Factor ModelAUC (95% CI)Change in AUC From Base Model*P*-Value[1](#tbl3fn1){ref-type="table-fn"}Hosmer-\
Lemeshow\
*P*-ValueImprovement in\
Sensitivity\
NRI (95% CI)[2](#tbl3fn2){ref-type="table-fn"}Improvement in Specificity\
NRI (95% CI)[2](#tbl3fn2){ref-type="table-fn"}Overall Improvement in Classification\
NRI (95% CI)[2](#tbl3fn2){ref-type="table-fn"}Australia (N = 1,035) Base model with traditional risk factors[3](#tbl3fn3){ref-type="table-fn"}0.72 (0.69 to 0.75)0.13 + *MC1R*0.73 (0.70 to 0.76)0.0110.050.47--0.02 (--0.10 to 0.06)0.35 (0.26 to 0.43)0.33 (0.21 to 0.45) + Pigmentation pathway0.74 (0.71 to 0.77)0.0190.0080.580.11 (0.03 to 0.19)0.26 (0.18 to 0.35)0.38 (0.26 to 0.50) + Nevus pathway0.72 (0.69 to 0.75)0.0010.54\<0.01--0.02 (--0.11 to 0.06)0.07 (--0.02 to 0.16)0.04 (--0.08 to 0.17) + Telomere, senescence, and other pathway0.72 (0.69 to 0.75)0.0020.360.14--0.06 (--0.14 to 0.02)0.16 (0.07 to 0.25)0.10 (--0.02 to 0.22) + All SNPs[4](#tbl3fn4){ref-type="table-fn"}0.74 (0.71 to 0.77)0.0230.0030.230.13 (0.05 to 0.21)0.29 (0.20 to 0.38)0.42 (0.30 to 0.54)Leeds (N = 1,460) Base model with traditional risk factors[3](#tbl3fn3){ref-type="table-fn"}0.65 (0.62 to 0.68)0.70 + *MC1R*0.67 (0.64 to 0.70)0.0140.020.34--0.10 (--0.16 to --0.03)0.27 (0.18 to 0.35)0.17 (0.07 to 0.28) + Pigmentation pathway0.68 (0.66 to 0.71)0.0310.00050.760.09 (0.02 to 0.15)0.22 (0.13 to 0.30)0.30 (0.20 to 0.41) + Nevus pathway0.65 (0.62 to 0.68)0.0000.980.81--0.03 (--0.10 to 0.03)0.06 (--0.03 to 0.14)0.02 (--0.08 to 0.13) + Telomere, senescence, and other pathway0.66 (0.63 to 0.69)0.0040.330.19--0.01 (--0.07 to 0.06)0.10 (0.02 to 0.19)0.10 (--0.01 to 0.21) + All SNPs[4](#tbl3fn4){ref-type="table-fn"}0.68 (0.65 to 0.71)0.0280.0020.100.09 (0.03 to 0.16)0.19 (0.11 to 0.28)0.29 (0.18 to 0.39)[^8][^9][^10][^11][^12]

Secondary analyses {#sec2.4}
------------------

Polygenic risk score and traditional risk factors had similar discrimination when compared side by side in separate models (respectively, 0.71 vs. 0.72 for Australia and 0.64 vs. 0.65 for Leeds). The incremental contribution of the polygenic risk score, including pathway-specific scores, was stronger when the models were based on risk estimates derived from the study datasets (AUC increased by 6.0% for Australia and 5.6% for Leeds), but after 10-fold cross-validation, the AUC increase was 2.0% and 1.2%, respectively (see [Supplementary Table S2](#appsec1){ref-type="sec"} online).

Cross-tabulation of polygenic risk score with traditional risk score {#sec2.5}
--------------------------------------------------------------------

In a cross-tabulation of polygenic versus traditional risk scores categorized as tertiles (low, average, high), 59% (Australia) and 49% (Leeds) of participants were categorized in the same (concordant) tertile ([Table 4](#tbl4){ref-type="table"}). Of participants with low traditional risk, 9% in Australia and 21% in Leeds had a high polygenic risk, indicating genetic susceptibility despite lack of phenotypic risk features. Conversely, 8% of participants in Australia and 18% in Leeds had a high traditional risk but a low polygenic risk.Table 4Cross-tabulation of polygenic risk score versus traditional risk score categorized in tertiles[1](#tbl4fn1){ref-type="table-fn"}Traditional Risk ScorePolygenic Risk Score, n (%)Tertile 1 (Lower Risk)Tertile 2 (Average Risk)Tertile 3 (Higher Risk)TotalAustralia Tertile 1 (lower risk)223 (65)91 (26)30 (9)344 (100) Tertile 2 (average risk)94 (27)160 (46)91 (26)345 (100) Tertile 3 (higher risk)27 (8)94 (27)225 (65)346 (100) Total3443453461,035Leeds Tertile 1 (lower risk)244 (50)138 (28)104 (21)486 (100) Tertile 2 (average risk)153 (31)209 (43)125 (26)487 (100) Tertile 3 (higher risk)89 (18)140 (29)258 (53)487 (100) Total4864874871,460[^13]

Parsimonious risk prediction models combining traditional and genomic risk factors {#sec2.6}
----------------------------------------------------------------------------------

[Table 5](#tbl5){ref-type="table"} lists traditional and genomic risk factors selected as a more parsimonious model for each dataset. The same genetic variants and traditional risk factors were assessed for inclusion in both models, but only those with *P* \< 0.20 in the multivariable model were retained. Traditional risk factors contributing to the final models for Australia and Leeds included family history of melanoma, nonmelanoma skin cancer, hair color, and nevus density. Other traditional UV and pigmentation variables retained in the final models differed between countries. A similar number of SNPs was selected for each model (19 for Australia, 18 for Leeds), but only seven overlapped. The AUCs for the Australian model were 0.77 (95% CI = 0.74--0.80) on internal validation and 0.72 (95% CI = 0.69--0.75) on external validation; for the Leeds model the AUCs were 0.72 (95% CI = 0.69--0.75) on internal validation and 0.77 (95% CI = 0.74--0.80) on external validation.Table 5Development of a risk prediction model for each dataset using model selection[1](#tbl5fn1){ref-type="table-fn"}Variable SelectedAustralian Model, Odds Ratio (95% CI)[2](#tbl5fn2){ref-type="table-fn"}Leeds Model, Odds Ratio (95% CI)[2](#tbl5fn2){ref-type="table-fn"}Traditional risk factors Family history of melanoma None1.001.00 1 or more relative1.61 (1.05--2.48)3.38 (1.33--8.59) Hair color Dark brown/black1.001.00 Light brown1.01 (0.71--1.44)1.15 (0.79--1.68) Fair or blonde1.82 (1.16--2.86)2.13 (1.32--3.42) Red2.76 (1.36--5.60)1.86 (0.96--3.58) Nevus density None1.001.00 Few1.19 (0.57--2.48)1.84 (1.09--3.11) Some3.13 (1.50--6.52)3.93 (2.27--6.79) Many5.36 (2.43--11.83)4.64 (2.36--9.15) Nonmelanoma skin cancer No1.001.00 Yes2.28 (1.19--4.37)3.86 (0.77--19.40) Blistering sunburn as a child None1.00--- 1 or more episodes0.80 (0.58--1.11)--- Sunbed use None1.00--- 1--10 sessions0.96 (0.61--1.51)--- \>10 sessions1.79 (1.01--3.20)--- Freckling as an adult None/very few---1.00 Few/some/many---0.73 (0.52--1.02) Eye color Brown or black---1.00 Green or hazel---1.05 (0.68--1.63) Blue or grey---1.39 (0.89--2.16) Sun exposure hours on weekends and vacations Quartile 1 (lower exposure)1.00 Quartile 2---0.52 (0.34--0.81) Quartile 3---0.61 (0.39--0.96) Quartile 4 (higher exposure)---0.44 (0.27--0.72)Genomic variants rs7412746 (*ARNT*)0.85 (0.67--1.06)0.81 (0.65--1.02) rs62211989 (*ASIP*)1.90 (1.33--2.71)1.91 (1.28--2.84) R151C (*MC1R*)2.59 (1.77--3.79)2.75 (1.83--4.13) R160W (*MC1R*)1.47 (1.00--2.16)1.70 (1.15--2.51) rs2487999 (*OBFC1*)1.40 (0.95--2.06)1.37 (0.93--2.01) rs132985 (*PLA2G6*)1.19 (0.95--1.48)0.85 (0.68--1.06) rs1393350 (*TYR*)1.32 (1.03--1.70)1.20 (0.95--1.52) rs6949072 (*AGR3*)1.28 (0.94--1.74)--- rs7274597 (*ASIP*)0.50 (0.31--0.81)--- rs76699054 (*CCND1*)1.40 (0.93--2.12)--- rs12527588 (*CDKAL1*)1.56 (0.95--2.55)--- rs3731217 (*CDKN2A*)0.79 (0.57--1.09)--- D84E (*MC1R*)2.18 (1.02--4.67)--- I155T (*MC1R*)2.60 (1.09--6.18)--- V60L (*MC1R*)1.74 (1.21--2.50)--- V92M (*MC1R*)1.70 (1.17--2.49)--- rs45430 (*MX2*)0.72 (0.57--0.90)--- rs3219090 (PARP1)0.73 (0.58--0.93)--- rs2736100 (*TERT*)0.74 (0.59--0.94)--- rs34585474 (*AGR3*)---1.27 (0.89--1.83) rs7781130 (*AGR3*)---1.59 (0.85--2.96) rs1801516 (*ATM*)---0.77 (0.55--1.07) rs700635 (*CASP8*)---1.27 (0.99--1.63) rs7776158 (*CDKAL1*)---1.36 (1.06--1.75) rs16953002 (*FTO*)---1.27 (0.93--1.73) R163Q (*MC1R*)---0.62 (0.36--1.09) D294H (*MC1R*)---4.11 (1.62--10.46) rs6517661 (*MX2*)---0.75 (0.53--1.07) rs113908778 (*RAD23B*)---0.55 (0.24--1.24) rs4436178 (*RAD23B*)---1.87 (0.82--4.26)[^14][^15][^16]

Discussion {#sec3}
==========

Our comprehensive assessment of the contribution of common genomic variants to melanoma risk prediction showed that a polygenic risk score is strongly associated with melanoma risk and improved the classification of people at high risk of melanoma beyond that identified from traditional risk factors. The incremental improvement to risk prediction was independent of ambient sun exposure because the increases were similar for the Leeds and Australian studies.

The incremental AUCs (2.3% for Australia, 2.8% for Leeds) and NRIs (0.42 for Australia, 0.29 for Leeds), based on published risk estimates, indicate a moderate improvement to risk prediction. Similar improvements in the AUC have been shown when adding SNPs to an established breast cancer risk model ([@bib23]), and smaller improvements were observed for prostate cancer ([@bib44]) and colorectal cancer ([@bib46]). Even relatively small improvements in the AUC have been shown to have clinical and public health utility and could be used in primary and secondary prevention to identify subgroups of the population at different levels of risk ([@bib20]). Genetic risk profiling is likely to contribute more in the future, because the proportion of variance in melanoma risk attributable to common genetic factors has been estimated to be at least 0.19 ([@bib31]).

The observed discriminative ability of the polygenic risk score for melanoma was higher than has been previously reported. A Greek study observed a 1.1% increase in the AUC when adding information from 15 SNPs to a phenotypic risk model ([@bib27]). A US study combining three different datasets found a statistically significant 3% increase in the AUC when adding 11 SNPs to a phenotypic risk model ([@bib17]); however the NRI when based on categories of risk (\<20%, 20%--50%, \>50%) was not significant because improvements in sensitivity were outweighed by reduced specificity. Conversely, in our study we observed a significant NRI that was driven by improvements in specificity and sensitivity, particularly specificity. The Women's Health Initiative cohort recently showed a 2-fold increased risk of melanoma for the highest versus lowest tertile of genetic risk score comprising 21 SNPs ([@bib6]), compared with a 3-fold difference in our studies. They had limited information on phenotypic risk factors ([@bib6]). We observed a larger improvement to risk prediction based on ORs from the study datasets, but this is likely due to model overfitting ([@bib47]).

The similarities between the results from Australia and Leeds suggest that the published risk estimates used to create the polygenic risk score are appropriate across populations of European origin. Although the AUC values for the comprehensive model were different between countries (0.74 for Australia and 0.68 for Leeds), this simply reflects more pronounced differences in demographic factors (age, sex, ethnicity) between case and control individuals in Australia than in Leeds.

SNPs from genes in pigmentation pathways, particularly *MC1R*, contributed the most to risk prediction, despite several pigmentation phenotype variables already being included in the traditional risk factor model. *MC1R* influences risk through pigmentation and nonpigmentation pathways, and *MC1R* variants are associated with a higher relative risk for melanoma in people who do not have a high-risk pigmentation phenotype ([@bib4], [@bib11], [@bib26]). This effect-measure modification of the association of *MC1R* with melanoma risk by phenotype ([@bib36]) is the reason that we incorporated phenotype-stratified ORs for *MC1R* variants in the models. We previously showed a 2.1% increase in the AUC when adding *MC1R* genotype to a traditional risk model based on risk estimates derived from the Australian dataset ([@bib12]), and a US study ([@bib38]) observed a statistically significant 1% increase.

Despite nevi being one of the strongest risk factors for melanoma ([@bib34]), SNPs from genes in nevus pathways did not improve risk prediction when based on published ORs, and they only modestly improved the AUC (by about 1%) when based on ORs derived from the dataset. Discrimination may improve with the discovery of new nevus-related genes ([@bib16]), but nevus phenotype measurement will likely continue to be important for risk prediction, perhaps because it reflects early-life sun exposure and genetic susceptibility ([@bib3]). SNPs from genes involved in other pathways unrelated to pigmentation and nevi, such as telomere length or senescence, were significantly associated with melanoma risk and made a modest contribution to risk prediction.

The more parsimonious risk prediction models that we developed showed good discrimination, because the AUCs remained at 0.72 or greater after internal and external validation. Not all SNPs and traditional risk factors were significantly associated with melanoma in the Australian and Leeds datasets, and the specific risk factors selected for the model differed between countries; this is probably a reflection of the studies' sample sizes.

Although our cross-tabulation of polygenic with traditional risk score tertiles estimated that 59% of people in Australia and 49% in Leeds have a genetic risk concordant with their traditionally estimated risk, a considerable proportion (9% and 21%, respectively) had a high polygenic risk despite having a low traditional risk. These people might be the most likely to benefit from genomic profiling given that they do not have the visible risk factors identified in public health campaigns. Conversely, a similar proportion had a high traditional risk but a low polygenic risk; knowing they have a low genetic susceptibility might worsen their sun-related behaviors. Our stratified analyses suggest that the improvement in discrimination might be better for those with a low or average traditional risk score. Studies are underway to evaluate the impact on sun-related behaviors of giving personalized melanoma genomic risk information ([@bib25], [@bib41]).

There are several strengths of our analysis, including the population-based design, external validation in independent datasets using the same questionnaires, relatively large sample sizes, comprehensive risk factor information, and evaluation of SNPs in distinct biological pathways. We also account for known gene-environment interactions by using phenotype-stratified ORs for *MC1R* variants in the models. Overall interpretation of the lack of major differences between the two countries in our findings is restricted because of the differing age ranges at recruitment (younger than 40 years for Australia, no age limit for the UK). Thus, these results cannot necessarily be extrapolated to older Australians. Our two studies had a slightly different mix of European ethnicities, with more Eastern European ancestry in the Australian study. Although our results were similar when restricted to English ethnic background, these ethnic differences might be further reflected in different pigmentation phenotypes and sun-related behaviors. Further validation in larger, diverse datasets is warranted. We have underestimated the incremental contribution of the polygenic risk score because not all the functional variants were known, but this is likely a modest attenuation; conversely, *MC1R* functional variants were included, and this may have strengthened its contribution relative to other genes or pathways.

Combining common genomic predictors of melanoma risk with traditional melanoma risk factors improves the discrimination of melanoma risk prediction models and can identify as being at high risk an important fraction of people of European origin who are at high genetic risk but low traditional risk. Variants in *MC1R* were responsible for over half of the discrimination improvement, but SNPs in other genes further improved risk prediction. Prediction models based on both genomic and traditional risk factors could increase the yet unproven capacity of models based only on traditional risk factors to motivate melanoma risk reduction behaviors.

Material and Methods {#sec4}
====================

Study samples {#sec4.1}
-------------

The Australian Melanoma Family Study was a multicenter, population-based, case-control family study of invasive cutaneous melanoma diagnosed between ages 18 and 39 years. Recruitment of case (n = 629) and control (n = 535) participants was locally coordinated in Sydney, Melbourne, and Brisbane, Australia. The study design, recruitment, data collection, and participant characteristics have been described ([@bib15]), and more details for both studies are provided in the [Supplementary Materials](#appsec1){ref-type="sec"} online.

The Leeds case-control study recruited population-based incident histopathologically confirmed invasive melanoma cases (n = 2,184) in patients aged between 18 and 82 years and population-ascertained control individuals (n = 513) ([@bib33], [@bib39]). This analysis focuses on those case individuals whose measurement protocols exactly matched the Australian study (n = 964).

Approval for the study was obtained from the ethics committees of the coordinating centers' institutions in Australia and Leeds and the cancer registries. All participants provided written informed consent.

Self-reported personal sun exposure {#sec4.2}
-----------------------------------

Comprehensive data on lifetime sun exposure was collected by telephone interview. Questions referred to the frequency of sunburn and time spent outdoors between 9 a.m. and 5 p.m. separately for weekdays, weekends, and vacations in warmer months and in cooler months ([@bib13], [@bib33]). Demographic information, ancestry, diagnoses of keratinocyte and other cancers, and family history information were also collected.

Pigmentary and nevus phenotype {#sec4.3}
------------------------------

Participants reported the skin color of their inside upper arm, eye color, natural hair color at age 18 years, freckling using Gallagher's freckle chart ([@bib29]), ability to tan, propensity to sunburn, usual tanning and sunburn response to prolonged or repeated exposure of skin to sunlight in summer, and nevus density (described pictorially as none, few, some, many) ([@bib15]).

Selection of gene variants {#sec4.4}
--------------------------

We selected 21 genes/loci (45 SNPs) that had a confirmed association with melanoma risk in genome-wide association studies ([@bib28]) or for one gene using whole-genome sequencing approaches (*MITF* rs149617956 variant) ([@bib48]) (see [Supplementary Table S3](#appsec1){ref-type="sec"} online). Polygenic risk scores summarized the combined effects of the SNPs using a published method ([@bib32]) (for more technical details, see [Supplementary Materials](#appsec1){ref-type="sec"}).

Statistical analysis {#sec4.5}
--------------------

### Analytic dataset {#sec4.5.1}

We excluded participants who did not give a blood sample or who failed genotyping, were missing data on traditional risk factors for melanoma, had germline *CDKN2A* pathogenic mutations or non-European ethnicity (on self-report or principal components analysis), and Australian controls 45 years or older at interview (because all Australian cases were diagnosed when patients were younger than 40 years). The analysis dataset thus included 1,035 participants (578 case individuals, 457 control individuals) from Australia and 1,460 participants (964 case individuals, 496 control individuals) from Leeds.

### Description of models {#sec4.5.2}

The primary analysis used ORs derived from published meta-analyses to prevent overfitting, that is, overestimation of the prediction accuracy that can occur when estimating the ORs from the same dataset that the predictions are made from ([@bib43], [@bib47]). The Australian and Leeds samples contributed data to the meta-analyses, but their data represented less than 10% of the total sample. In secondary analyses presented in [Supplementary Table S2](#appsec1){ref-type="sec"}, we show the results based on ORs derived from the study datasets. The published ORs and ORs derived from the datasets are shown in [Supplementary Table S3](#appsec1){ref-type="sec"} for genomic variants and [Supplementary Table S4](#appsec1){ref-type="sec"} online for traditional risk factors. The published ORs for the traditional risk factors were from fully adjusted models in meta-analyses, and we categorized our variables the same as the published data. The published ORs for genomic variants were obtained from a meta-analysis of genome-wide association studies ([@bib28]), using pooled ORs from a fixed effects model or random effects where there was evidence of heterogeneity (*I*^2^ ≥ 31%). Because the association of *MC1R* with melanoma risk is modified by phenotype ([@bib36]), we incorporated phenotype-stratified ORs for each of the *MC1R* variants for models that included traditional risk factors; for this stratification, participants were classified as having a sun-sensitive phenotype if they had one or more of freckles (few, some, many), red hair, or skin that usually or always burns.

[Supplementary Table S3](#appsec1){ref-type="sec"} shows the biological pathway/s through which each gene is thought to influence melanoma risk: pigmentation (14 genes); nevus (7 genes); and telomere, senescence, and other pathways (5 genes). Classification of pathways was based on associations of SNPs with each of these traits ([@bib7], [@bib8], [@bib16], [@bib28]), and genes could be allocated to multiple pathways.

Logistic regression models were used to assess associations between melanoma and traditional and genomic risk factors, adjusted for demographic and study design factors: age, sex, city of recruitment (Australia only), and self-reported European ancestry (British, other Northern European, Southern/Eastern European, mixed/other European); ancestry was included as a covariate to minimize confounding by ethnicity. The base risk prediction model included well-established independent traditional risk factors and UV exposure variables (hair color, skin color, eye color, freckling as an adult, nevus density, reported skin photosensitivity, personal history of keratinocyte cancer, first-degree family history of melanoma, blistering sunburns as a child, vacation sun exposure, and sunbed use). The incremental contribution of melanoma risk SNPs was assessed overall, by biological pathway, and for *MC1R* alone.

### Model performance {#sec4.5.3}

The ability of the model to discriminate between case and control individuals was evaluated by calculating the AUC, NRI, and OR per standard deviation (adjusted for age and sex using the OPERA method \[[@bib22]\]). The AUC is the probability that the predicted risk is higher for a case individual than for a control individual and ranges from 0.5 (equivalent to a coin toss) to 1.0 (perfect discrimination). The NRI quantifies overall improvement in model sensitivity and specificity; it quantifies movement of case and control individuals to higher or lower predicted risk probabilities when a new risk model is applied ([@bib30]). Because there are no established risk thresholds for melanoma, we used category-free continuous NRI ([@bib37]). We used the Hosmer-Lemeshow goodness-of-fit test to assess calibration, that is, the agreement between observed and predicted probabilities of melanoma ([@bib43]). For the secondary analyses that used ORs derived from the study datasets, we performed 10-fold cross-validation as a measure of internal validation to help correct for overfitting ([@bib43]).

### Cross-tabulation of polygenic risk score versus traditional risk score {#sec4.5.4}

Traditional and polygenic risk scores (each based on published risk estimates) were categorized into tertiles and cross-tabulated to compare the concordance of genomic with traditional risk. The traditional risk score variable was derived from the predicted probability of melanoma for each individual, based on β-values from a logistic regression model with melanoma (case-control) status as the outcome and traditional risk factors as predictors.

Data were analyzed using SAS, version 9.4 (SAS Institute, Cary NC), and statistical significance was inferred at two-sided *P* less than 0.05. We reported the study according to published guidelines ([@bib9], [@bib24]).
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[^1]: Australian Melanoma Family Study investigators: Graham J. Mann, Anne E. Cust, Helen Schmid, John L. Hopper, Joanne F. Aitken, Bruce K. Armstrong, Graham G. Giles, Elizabeth Holland, Richard F. Kefford, Mark A. Jenkins

[^2]: Leeds Case-Control Study investigators: Julia A. Newton Bishop, Paul Affleck, Jennifer H. Barrett, D. Timothy Bishop, Jane Harrison, Mark M. Iles, Juliette Randerson-Moor, Mark Harland, John C. Taylor, Linda Whittaker, Kairen Kukalizch, Susan Leake, Birute Karpavicius, Sue Haynes, Tricia Mack, May Chan, Yvonne Taylor, John Davies, Paul King

[^3]: Leeds case and control individuals were unselected for age at diagnosis. In Australia, all case individuals were younger than 40 years at diagnosis, and all population control individuals were younger than 40 years when ascertained. Case and control individuals could be up to age 44 years at interview for this analysis.

[^4]: Self-reported.

[^5]: Models are adjusted for demographic and study design factors of age, sex, city of recruitment, and European ancestry.

[^6]: *P*-value for interaction comparing trends across countries.

[^7]: Odds ratio per adjusted standard deviation, stratified by location (Australia/Leeds) and adjusted for age and sex, using the OPERA method ([@bib22]).

[^8]: Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; NRI, net reclassification improvement; SNP, single nucleotide polymorphism.

[^9]: Chi-square *P*-value for the difference in the AUC when compared with the base model.

[^10]: Based on continuous NRI. Improvement in sensitivity is calculated from reclassification of case individuals improvement in specificity is calculated from reclassification of control individuals, and overall improvement combines the improvements in sensitivity and specificity.

[^11]: Traditional factors include hair color, skin color, eye color, freckling as an adult, skin photosensitivity, self-reported nevi, sunbed use, keratinocyte cancer personal history, first degree family history of melanoma, vacation sun exposure, and blistering sunburns as a child, as well as the demographic and study design factors of age, sex, city of recruitment, and European ancestry.

[^12]: Added as a polygenic risk score, comprising 45 SNPs in 21 genes. The SNPs in each pathway can overlap; the pigmentation pathway includes 14 genes (31 SNPs); nevus pathway includes 7 genes (13 SNPs); and telomere, senescence, and other pathways includes 5 genes (9 SNPs).

[^13]: Both models are adjusted for demographic and study design factors: age, sex, city of recruitment, and European ancestry.

[^14]: Abbreviation: CI, confidence interval.

[^15]: A risk prediction model was developed separately for each dataset using a backward selection process in which traditional and genomic risk factors with *P* \< 0.20 were retained in the multivariable model in addition to forced variables age, sex, city of recruitment, and European ancestry. The same genetic variants and traditional risk factors were assessed for inclusion in both models.

[^16]: Odds ratios derived from the respective dataset, adjusted for all other variables in the model. For genomic variants, the per-allele odds ratio is presented. Values left blank indicate that the factor was not included in the final model for that dataset (Australia/Leeds). The areas under the curve for the Australian model were 0.80 (95% CI = 0.77--0.83) from the development model, 0.77 (95% CI = 0.74--0.80) from internal validation (10-fold cross-validation), and 0.72 (95% CI = 0.69--0.75) from external validation using the Leeds dataset. The areas under the curve for the Leeds model were 0.77 (95% CI = 0.73--0.80) from the development model, 0.72 (95% CI = 0.69--0.75) from internal validation, and 0.77 (95% CI = 0.74--0.80) from external validation using the Australian dataset. Both models were well calibrated in the external datasets (Hosmer-Lemeshow *P* = 0.57 for both).
